APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 946.00

Change

0.00 (0.00)%

Market Cap

INR 186.08B

Volume

0.29M

Avg Analyst Target

INR 1,085.00 (+14.69%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (API) and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, anti-diabetic, gynecology, acute, gastroenterology, ophthalmology, dermatology, nephrology/urology, orthopedics, cancer, inflammation, autoimmune diseases, anti-infective, cold and cough, and metabolic disorders, as well as hospital care and animal health. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India. Address: Alembic Road, Vadodara, India, 390003

Company Website : http://www.alembicpharmaceuticals.com

Address : Alembic Road, Vadodara, India, 390003

Employees : 12,160

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.69

52 Week High : 1,128.45

52 Week Low : 851.81

200 Day Moving Average : 967.67

50 Day Moving Average : 976.63

Shares Held By Insiders : 70.09%

Shares Held by Institutions : 13.91%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

 INR1,665.14B 57.36 30.91
DIVISLAB:NSE Divi's Laboratories Limited

N/A

 INR1,280.82B 64.55 42.75
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

 INR899.04B 52.31 22.27
CADILAHC:NSE Cadila Healthcare Limited

N/A

 INR629.86B 29.52 21.21
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

 INR564.67B 10.59 6.61
LUPIN:NSE Lupin Limited

N/A

 INR536.29B 44.21 20.35
ALKEM:NSE Alkem Laboratories Limited

N/A

 INR405.89B 25.61 18.74
LAURUSLABS:NSE Laurus Labs Limited

N/A

 INR347.61B 35.44 23.16
IPCALAB:NSE Ipca Laboratories Limited

N/A

 INR279.54B 24.46 16.37
NATCOPHARM:NSE NATCO Pharma Limited

N/A

 INR199.56B 45.30 26.80

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.27% 13% F 7% F
Dividend Return 1.34% 40% F 63% D
Total Return -7.92% 11% F 8% F
Trailing 12 Months  
Capital Gain -3.49% 5% F 6% F
Dividend Return 1.43% 93% A 51% F
Total Return -2.06% 5% F 6% F
Trailing 5 Years  
Capital Gain 60.27% 49% F 59% F
Dividend Return 4.66% 89% B+ 56% F
Total Return 64.93% 49% F 59% F
Average Annual (5 Year Horizon)  
Capital Gain 17.63% 49% F 67% D+
Dividend Return 0.60% 61% D- 65% D
Total Return 18.23% 48% F 67% D+
Risk Return Profile  
Volatility (Standard Deviation) 35.69% 80% B- 73% C
Risk Adjusted Return 51.09% 56% F 82% B-
Market Capitalization 186.08B 83% B 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 15.56 76% C 66% D
Price/Book Ratio 3.62 57% F 30% F
Price / Cash Flow Ratio 12.72 67% D+ 38% F
EV/EBITDA 12.03 73% C 55% F
Management Effectiveness  
Return on Equity 27.77% 89% B+ 93% A
Return on Invested Capital 21.77% 79% C+ 91% A-
Return on Assets 12.77% 81% B- 93% A
Debt to Equity Ratio 3.90% 53% F 67% D+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.69 61% D- 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector